Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712270 · ClinicalTrials.gov registry record · Phase 4
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
A Phase 4 study, sponsored by Kettering Health Network.
- Terminated
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT00712270: Clinical Trial Phase 4 study, sponsored by Kettering Health Network.
NCT00712270 is a Phase 4 study that was terminated before completion, run by Kettering Health Network. The registered enrollment target is 21 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00712270, a Phase 4 study, was terminated before completion, sponsored by Kettering Health Network.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs. This could help doctors prescribe the medication that will work best for each individual.
Interventions
- DRUG Risperidone
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
Why NCT00712270 stopped before completion
NCT00712270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT00712270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00712270 about?
NCT00712270 is a clinical study titled "Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia". This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs. This could help doctors prescribe the medication that will work best for each individual.
What is the current status of trial NCT00712270?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2005-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00712270?
The interventions under investigation include: Risperidone (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00712270?
This trial is sponsored by Kettering Health Network, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00712270's enrollment target sits among peer trials
21 1742nd of 2000 higher than 248 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia